145464-28-4

Basic information

• Product Name: Capromab Pendetide
• Synonyms: Capromab Pendetide;Cytogen 356;Immunoglobulin G 1 (mouse monoclonal 7E11-C5.3 anti-human prostatic carcinoma cell), disulfide with mouse monoclonal 7E11-C5.3 light chain, dimer, N(sup 6)-(N-(2-((2-(bis(carboxymethyl)amino)ethyl)(carboxymethyl)amino)ethyl)-N-(carboxymethyl)glycyl)-N(sup 2)-(N-glycyl-L-tyrosyl)-L-lysine conjugate;Oncoscint prostate;Prostascint
• CAS NO: 145464-28-4
• Molecular Formula: C10H15N5O11P2
• Molecular Weight: 443.200522
• Mol File: 145464-28-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Capromab Pendetide(CAS DataBase Reference)
• NIST Chemistry Reference: Capromab Pendetide(145464-28-4)
• EPA Substance Registry System: Capromab Pendetide(145464-28-4)

Safety Data

• Hazardous Substances Data: 145464-28-4(Hazardous Substances Data)

Usage

Uses

Monoclonal antibody.

General Description

Capromab (ProstaScint Kit for the preparation of In-111capromab pendetide, murine) is an MAb (murine IgG1 κ)that derives from an initial sensitization with a glycoproteinexpressed by prostate epithelium known as prostate surfacemembrane antigen (PSMA). The MAb recognizes PSMAspecifically and thus is specific for prostate adenocarcinomas.The drug is used in newly diagnosed patients withproven prostate cancer who are at high risk for pelvic lymphmetastasis. PSMA has been found in many primary andmetastatic prostate cancer lesions. The cytoplasmic domainmarker 7E11-C5.3 reacts with more than 95% of adenocarcinomasevaluated.To join the indium-111 to the antibody, a linker-chelatoris used. This moiety is glycyltyrosyl-(N-ethylenetriaminepentaaceticacid)-lysine HCl.